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Abstract
The opportunistic human pathogen, Pseudomonas aeruginosa, is a major cause of infections in chronic wounds, burns and
the lungs of cystic fibrosis patients. The P. aeruginosa genome encodes at least three proteins exhibiting the characteristic
three domain structure of autotransporters, but much remains to be understood about the functions of these three proteins
and their role in pathogenicity. Autotransporters are the largest family of secreted proteins in Gram-negative bacteria, and
those characterised are virulence factors. Here, we demonstrate that the PA0328 autotransporter is a cell-surface tethered,
arginine-specific aminopeptidase, and have defined its active site by site directed mutagenesis. Hence, we have assigned
PA0328 with the name AaaA, for arginine-specific autotransporter of P. aeruginosa. We show that AaaA provides a fitness
advantage in environments where the sole source of nitrogen is peptides with an aminoterminal arginine, and that this
could be important for establishing an infection, as the lack of AaaA led to attenuation in a mouse chronic wound infection
which correlated with lower levels of the cytokines TNFa, IL-1a, KC and COX-2. Consequently AaaA is an important virulence
factor playing a significant role in the successful establishment of P. aeruginosa infections.
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Introduction
Pseudomonas aeruginosa is an important human pathogen causing a
myriad of infections including those of burns, trauma wounds and
the eyes [1]. This Gram-negative bacterium is perhaps best known
for being the leading cause of morbidity in cystic fibrosis (CF)
patients, with 80% of adult CF patients carrying P. aeruginosa in
their lungs [2,3], and has recently gained notoriety by being
classified as a ‘superbug’ by the media. The latter emanates from
the intrinsic resistance that this opportunistic pathogen has against
antibiotics [4,5], and its prominence as a cause of nosocomial
infections (there are an estimated 10,000 cases each year in UK
hospitals) [5–8].
The success of P. aeruginosa as a pathogen is attributed to the
immense battery of virulence determinants that it possesses. These
virulence factors include toxins, proteases, lipases, and rhamno-
lipids [9], which are regulated by a complex hierarchy of
regulators that include cell-to-cell communication networks [10–
12]. One of the least-studied families of virulence factors produced
by P. aeruginosa is the autotransporters (ATs). ATs are character-
ized by a tripartite structure encompassing (i) an N-terminal signal
peptide that enables translocation across the inner membrane, (ii)
a C-terminal domain that forms a b-barrel in the outer membrane,
and (iii) a central passenger domain that bears the functional
domain of the AT. ATs have diverse functions, but all of those
characterized to date in pathogens contribute to the virulence of
their producing bacterium [13,14]. The functions of ATs include
agglutination (e.g. Ag43 [15]), vacuolating toxins (e.g. VacA
[16,17]) and serine proteases. The serine protease ATs of the
Enterobacteriaceae are termed SPATES, and their functions as we
understand them have been comprehensively reviewed [13,18].
SPATES tend to be the most abundant proteins secreted during in
vitro growth of pathogenic Enterobacteriaceae, and usually exhibit
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multifunctional virulence-related activities. Other ATs with
proteolytic activities include NalP, which processes other ATs
and is responsible for the release of the lactoferrin-binding protein
B (LpbB) from the surface of Neisseria meningitidis [19]. Additional
ATs involved in surface maturation of proteins include SphB1 of
Bordetella pertussis [20] and AasP of Actinobacillus pleuropneumoniae
[21]. Some ATs use their proteolytic activities to direct their own
release via autoproteolysis from the surface of the bacteria that
produces them, e.g. IgA protease of Neisseria gonnorhoeae [22], and
Hap from Haemophilus influenzae [23]. In some cases, although the
proteolytic AT clearly augments virulence and influences interac-
tions with host cells, its precise role is uncertain, e.g. PfaI from
Pseudomonas fluorescens [24]. There are also examples where ATs
combine proteolysis with other functions to ameliorate pathoge-
nicity, e.g. the Proteus mirabilis toxic agglutinin Pta [25].
Whilst ATs appear to have the simplest mechanism of secretion
found in Gram-negative bacteria and constitute a subgroup of the
type V secretion system, the mechanistic details of AT secretion
are currently controversial and need further study [26]. Originally
it was proposed that the b-barrel acted as the outer membrane
conduit to secrete the passenger domain to the bacterial surface
[22]. More recently it has become evident that additional proteins
may be involved in this process, most notably the recently
discovered Bam complex [27–30], but the mechanistic steps are
hotly debated [14,18,26–29,31–33]. Once at the bacterial cell
surface, some ATs, such as IgA protease from Neisseria gonorrohoeae,
release their passenger domains into the extracellular matrix [22],
whilst others like the Ag43 produced by enteroaggregative E. coli
maintain the functional passenger domain on their cell surface
[15].
The genome of P. aeruginosa encodes a number of proteins with a
type V mode of secretion [9], including a recently described
member of a novel subgroup (type Vd [34]). However, it only
harbours three genes encoding proteins predicted to have the
characteristic AT b-barrel domain. One of these, the esterase
EstA, functions to alter the levels of extracellular rhamnolipids,
modulates twitching, swimming and swarming motility and
influences the formation and architecture of biofilms [35,36].
The isolation of an attenuated mutant indicates that EstA
contributes to the virulence of P. aeruginosa, although the
underlying mechanisms require further investigation [37]. The
two other ATs in P. aeruginosa are not as well studied. While
PA3535 is a putative serine protease [38], there is currently no
published experimental evidence to confirm this. Similarly, little is
known of the function of PA0328, although it is annotated as an
aminopeptidase. The MEROPS database of peptidases predicts
PA0328 to be a member of the M28 family of peptidases [39]. The
M28 family encompasses both amino and carboxy specific
peptidases which tetrahedrally coordinate two zinc ligands using
residues including histidine, aspartic acid and glutamic acid to
create their catalytic pocket [40–43].
Here, we describe the characterisation of PA0328. Since we
demonstrate that PA0328 is an AT that specifically removes
aminoterminal arginine from peptides, we propose to name it the
Arginine-specific Aminopeptidase of P. aeruginosa: AaaA. In
addition to characterizing the surface localization of AaaA, and
its ability to confer a growth fitness advantage, we describe the
influence that AaaA has on the pathogenicity of P. aeruginosa, and
put forward potential mechanistic models for this role.
Results
AaaA is an AT that is not released from the bacterial cell
surface
To verify that the predicted AT domain located in the C-
terminal of AaaA functions to direct it to the outer membrane
(OM), and to determine whether there is subsequent proteolytic
release of the passenger domain, the cellular localisation of AaaA
was first analysed. To do this, aaaA was inserted adjacent to an
IPTG inducible promoter with a C-terminal His-tag resulting in
the plasmid pDEST42::aaaA. The protein production profiles
observed by SDS-PAGE and immunoblotting with the a-His
antibody of this clone expressed in E. coli DH5a revealed a protein
associated with the bacterial cells with a predicted mass of
approximately 85 kDa which is larger than 70.4 kDa predicted
from the sequence of the encoding gene. Peptide mass finger-
printing confirmed that this protein was indeed AaaA, lacking its
N-terminal signal peptide (not shown). Subcloning into pET21a
was undertaken as described in materials and methods to enable
overexpression of aaaA from a T7 promoter (Figure 1A, lane 2).
The resultant protein was purified, verified by peptide mass
spectroscopy, and used to generate specific polyclonal antisera to
aid AaaA detection.
To establish whether AaaA was exposed on the cell surface, the
AaaA-specific polyclonal antiserum was used to detect whether
exogenously introduced trypsin could degrade AaaA (Figure 1). To
enable detection in P. aeruginosa as well as E. coli, aaaA was cloned
into the shuttle vector pME6032 (creating pME6032::aaaA),
introduced into the P. aeruginosa aaaA-deficient mutant (DaaaA;
Figure S1) and induced with IPTG. The low copy number of
pME6032::aaaA in E. coli DH5a led to AaaA levels too low to be
detected easily by immunoblot. Therefore, AaaA was overpro-
duced from pET21a::aaaA in E. coli LEMO2, a strain reported to
tolerate higher levels of membrane proteins. The cultures were
split into aliquots. These aliquots were treated with trypsin with or
without a protease inhibitor, followed by immunoblotting with a-
His (not shown) or a-AaaA (Figure 1B,C). As controls, cytoplasmic
RpoS (for P. aeruginosa) or IscS (for E. coli) were detected similarly,
and found not to be degraded as much as AaaA in the presence of
Author Summary
We present a new Pseudomonas aeruginosa virulence
factor that promotes chronic skin wound infections. We
propose the name AaaA for this cell-surface tethered
autotransporter. This arginine-specific aminopeptidase
confers a growth advantage upon P. aeruginosa, providing
a fitness advantage by creating a supply of arginine in
chronic wounds where oxygen availability is limited and
biofilm formation is involved. To our knowledge, this is the
first mechanistic evidence linking the upregulation of
genes involved in arginine metabolism with pathogenicity
of P. aeruginosa, and we propose potential underlying
mechanisms. The superbug P. aeruginosa is the leading
cause of morbidity in cystic fibrosis patients. The ineffec-
tive host immune response to bacterial colonization is
likely to play a critical role in the demise of these patients,
making the possibility that AaaA could interface with the
innate immune system, influencing the activity of iNOS
and consequently the host’s defence against invading
pathogens. The surface localisation of AaaA makes it
accessible to inhibitors that could reduce growth of P.
aeruginosa during colonisation and alter biofilm formation,
potentially improving the efficacy of current antimicrobi-
als. Indeed, structurally related aminopeptidases play a
central role in several disease states (stroke, diabetes,
cancer, HIV and neuropsychiatric disorders), and inhibitors
alleviate symptoms.
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trypsin. When the cells were lysed before treatment commenced,
greater degradation of AaaA and the cytoplasmic control protein
was observed. The intensity of the fully mature AaaA protein was
reduced in both whole and lysed cells. The presence of trypsin
inhibitor prevented degradation by trypsin (Figure 1B,C). This
suggested to us that the passenger domain of AaaA is anchored to
the bacterial cell surface, where it is accessible to trypsin digestion,
consistent with it being an uncleaved AT. No released AaaA
passenger domain could be detected in culture supernatants.
To visualise this more directly, P. aeruginosa DaaaA(p-
ME6032::aaaA) was subjected to confocal immunofluorescent
microscopy with a-AaaA, and its localisation was compared with
that of FM1-43, a fluorescent marker that interacts with lipid
membranes. Whilst no signal was detected using the pre-immune
Figure 1. The passenger and b-barrel domains of AaaA remain connected and are tethered to the cell surface. E. coli LEMO21 bearing
the empty vector pET21a or pET21a::aaaA was grown to mid exponential phase in LB, and induced with 1 mM IPTG for 1 h. Following harvesting,
washing and resuspension in PBS-Hepes, half of the cells were lysed by sonication. The whole and lysed cells were split into three aliquots and
incubated with (T) or without (2) trypsin according to the Materials and Methods. Trypsin inhibitor was added at the same time as trypsin to one of
the aliquots (T+I). Proteins were separated through a 9% SDS PAGE and stained with Coomassie Blue (Panel A) or subjected to immunoblotting with
either a-AaaA (Panel B, top), or a-IscS (Panel B, bottom) antisera. A parallel experiment was performed with P. aeruginosa DaaaA bearing either
pME6032 or pME6032::aaaA. LB overnight cultures were diluted 1:100 in fresh LB, grown for 3 h at 37uC, and induced with 1 mM IPTG for 1 h. The
immunoblot of the P. aeruginosa proteins is shown in Panel C, with the cytoplasmic control protein being detected with a-RpoS in the bottom panel.
The sizes of molecular weight markers are shown in kDa on the left, and the position of AaaA is indicated. In Panels B and C, densitometry was used
to estimate the quantity of the cytoplasmic protein and the full length AaaA (indicated with the asterisk) detected in the immunoblots using imageJ
software. The fold change of AaaA, IscS and RpoS are shown below the images of the respective immunoblots. The images in Panels D and E were
captured by confocal fluorescent microscopy. P. aeruginosa DaaaA(pME6032::aaaA) was grown and induced as described for Panel C, probed with
FM1-43 and either a-AaaA (Panel E) or pre-immune serum (Panel D). Incubation with donkey a-rabbit alexa fluor 680-conjugated secondary antibody
(red) was performed before images were captured at either the apex or cross section of individual cells (as indicated in the dotted lines of the
cartoon). Green fluorescence from FM1-43 (top Panel, green circle in cartoon), red fluorescence from alexa fluor 680 (middle Panel, red stars in
cartoon), merged 2D and merged 3D shadowed images are shown.
doi:10.1371/journal.ppat.1002854.g001
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serum, a-AaaA clearly detected AaaA primarily on the surface of
P. aeruginosa (Figure 1D, E).
To determine whether the surface exposed AaaA was integrated
into the outer membrane, E. coli LEMO21(pET21a::aaaA) was
induced and fractionated. Clean separation of cytoplasmic,
periplasmic, inner membrane and outer membrane fractions was
verified by immunoblotting with marker proteins: IscS (cysto-
plasm), LEP (inner membrane), and TolC (outer membrane).
Immunoblotting of AaaA revealed that this protein was only
detected in the OM (Figure 2A–D).
AaaA is an arginine-specific aminopeptidase
The passenger domains of ATs characteristically bear the
functional active site. Thus, to provide an initial clue towards the
function of AaaA, BLAST searches were performed using
sequences corresponding to the passenger domain of AaaA.
Similarity to aminopeptidase proteins was revealed, confirming the
annotation of AaaA [38]. Closer analysis using the MEROPS
database (employing a BLAST search of this database using the
full length sequence of AaaA), identified AaaA as a member of the
M28.005 family. The protein with the closest similarity (63%
sequence identity over the entire length of the proteins) was
another uncharacterized AT from the plant pathogen Pectobacterium
carotovorum (ECA2163). Other members of the wider M28 family
include both amino and carboxy peptidases with different
specificities, the best studied of which being the aminopeptidase
A of Streptomyces griseus (SGAP) and the leucine-specific aminopep-
tidase of Vibrio proteolyticus (VpAP), which have been crystallized
[42–48]. Predicted active site catalytic and ligand binding site
residues are 100% conserved between AaaA and the other
members of the M28.005 family (Figure 3A,B), strongly suggesting
that AaaA has an aminopeptidase activity.
P. aeruginosa produces a variety of proteases including elastase
(LasB), alkaline protease, LasA protease, PrpL, AprA, and a
leucine-specific aminopeptidase (paAP; PA2939, [49]). Since the
activation of at least one of these (paAP) is mediated by another
(elastase), and because the degradation product of one may be the
substrate of another, we thought it prudent to investigate the
proteolytic function of AaaA in its endogenous background. To do
this, an in-frame deletion mutant of aaaA, was constructed in
PAO1 (see materials and methods, Table 1, Figure S1A).
In the first instance, a phenotypic comparison between PAO1
and the derived PAO1DaaaA mutant was conducted to ascertain
whether there were any gross changes in proteolytic capability.
This analysis revealed that both PAO1 and PAO1DaaaA generated
similar zones of clearing on agar plates containing skimmed milk,
which correlated with no difference in casein degradation using
the azocasein degradation assay (materials and methods, data not
shown). Similarly there was no change in elastin degradation using
the elastin-congo red degradation assay or haemolysis on blood
agar plates (materials and methods, data not shown). Having been
unable to detect a difference in the degradation of proteins known
to be broken down by P. aeruginosa, we sought to identify the
specificity of the predicted aminopeptidase activity of AaaA. To do
this, an assay used for a similar purpose with other members of the
M28 family was employed. For this assay, amino acids linked to p-
nitroanilide are incubated with the suspected peptidase. Amino-
peptidase activity is detected when the pseudo-peptide bond of the
p-nitroanilide derivative is broken, and the chromophore released
(4-nitroanilide) is monitored by a change at 405 nm over time.
Both PAO1 and PAO1DaaaA were only able to degrade
methionine-p-nitroanilide and leucine-p-nitroanilide slowly and to
a limited extent during 24 h, whilst a commercial preparation of
SGAP clearly released maximal levels of 4-nitroanilide from
leucine-p-nitroanilide and methionine-p-nitroanilide in less than
2 h (Figure S2 A,B,C). As one of the closest homologues (57%
sequence identity in the passenger domain) of AaaA, the IAP
aminopeptidase produced by E. coli, enables isoenzyme conversion
of alkaline phosphatase by removing the terminal arginine residue
from each protomer within the alkaline phosphatase dimer [50]
and because aaaA expression levels are altered in the absence of the
arginine-dependent regulator ArgR [51], we hypothesized that
AaaA may release arginine from peptides. To test this, we assayed
the ability of PAO1 and PAO1DaaaA to release 4-nitroanilide from
arginine-p-nitroanilide. Whilst the wild type efficiently degraded
the arginine-p-nitroanilide to fully release 4-nitroanilide within
Figure 2. AaaA localises to the outer membrane of E. coli. E. coli LEMO21 bearing the empty vector (pET21a: Panels E–H), pET21a::aaaA (WT:
Panels A–D) or similar plasmids producing one of four site directed mutants (pET21a::aaaAG89A (G89A: Panels I–L), pET21a::aaaAH100A (H100A:
Panels M–P), pET21a::aaaAE147A (E147A: Panels Q–T), pET21a::aaaAE149A (E149A: Panels U–X)) were grown until mid-exponential phase in LB, and
induced with 1 mM IPTG for 1 h. Each strain was divided into aliquots to obtain the different fractions of the cell according to the materials and
methods (C: cytoplasm; I: inner membrane; P: periplasm; O: outer membrane). Proteins were separated through a 9% SDS PAGE and immunoblotted
with a-AaaA (Panels A,E,I,M,Q,U), a-IscS (Panels B,F,J,N,R,V), a-LEP (Panels C,G,K,O,S,W) and a-TolC (Panels D,H,L,P,T,X) antisera. The
positions of AaaA, IscS, LEP and TolC protein are indicated on the left.
doi:10.1371/journal.ppat.1002854.g002
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Figure 3. AaaA is a member of the M28 family of aminopeptidases and site directed mutagenesis confirms that predicted active site
residues of AaaA contribute to arginine aminopeptidase activity. (Panel A) ClustalW2 multiple sequence alignment of the predicted active
sites of the holotype enzymes for the four M28 subfamilies plus the two M28C ATs AaaA and ECA2163 (from Pectobacterium caratovora subspecies
carotovorum). Identical residues are indicated by an asterisk, and similar residues by a colon or full stop. The residues highlighted in the black box are
those shown to be functional within the active site. Underlining indicates the position of the conserved residues chosen for site directed
mutagenesis. The holotype enzymes shown are: Streptomyces griseus aminopeptidase S (SGAP) M28.003/MER002161 (M28A), glutamate
carboxypeptidase II M28.010/MER002104 (M28B), E. coli IAP aminopeptidase M28.05/MER001290 (M28C), and aminopeptidase AP1 M28.002/
MER001284 (M28E). All the sequences were taken from UniProt database software (http://www.uniprot.org/). (Panel B) Crystal structure of the
M28.003 founding aminopeptidase (SGAP) with the residues that are conserved in an alignment with PA0328 highlighted in yellow. The Red balls
indicate the two intercalated metal ions. Panel C indicates the positions of the residues in AaaA that were selected for mutagenesis. The structure
shown was predicted for AaaA using an alignment with and crystal structure of SGAP as the guide. All residues mutated were predicted to be in the
active site (A) except G89 which is predicted to lie on an outward facing loop of the protein (B). All mutations were substitutions to Alanine. E. coli
LEMO21 containing a pET21a vector alone (2) or with WT AaaA or one of the mutated versions (indicated by the mutation) were grown in LB until
OD600 of 0.5, and induced with IPTG for 3 h. Whole cell extracts were separated through a 9% SDS PAGE and stained with Coomassie Blue (Panel E),
or subjected to immunoblotting using a-AaaA antibody (Panel D). The asterisks indicate products of aaaA, and the arrow indicates full length AaaA.
Arginine-Specific Aminopeptidase Pseudomonas
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8 h, the PAO1DaaaA mutant did not do this, even after 24 h of
incubation (Figure 4A). To verify that this difference was due to
the deletion of aaaA, complementation was performed with
plasmid pME6032::aaaA. In comparison to the empty vector
(pME6032), pME6032::aaaA significantly repaired the mutant’s
ability to degrade arginine-p-nitroanilide, giving higher levels of
degradation than the wild type.
To confirm that the arginine-p-nitroanilide degradation was a
direct consequence of AaaA, the activity of AaaA overproduced in
the heterologous host E. coli was measured. As can be seen in
Figure 4B, maximal release of 4-nitroanilide was achieved within
5 h by E. coli (pME6032::aaaA) whilst E. coli (vector) did not
degrade arginine-p-nitroanilide significantly within 24 h. Together
these data strongly suggest that AaaA is an arginine-specific
aminopeptidase.
Site directed mutagenesis reveals key residues in AaaA
are involved in aminopeptidase activity
To establish that the predicted active site within AaaA is
responsible for the measured arginine-specific aminopeptidase
activity, site directed mutagenesis targeted at predicted key
residues was undertaken. To identify key residues in the catalytic
site, we took advantage of the crystal structure of SGAP (referred
to as 1xjo on the protein structure database). Alignments
(Figure 3A) had shown that residues involved in catalysis were
conserved between AaaA and SGAP, so these were mapped onto
the crystal structure (Figure 3B). It was evident from this that the
active site pocket was well conserved, as were key residues
stabilising structural elements.
Seven residues were chosen (underlined in Figure 3A), and site
directed mutagenesis used to convert them to alanines. Six of the
residues mapped within the predicted catalytic pocket of AaaA
(H100, D102, E147, E149, D176, D277), and the other was
located on a surface exposed, unstructured loop (G89) (Figure 3C).
Three of the mutants with amino acid substitutions predicted to lie
within the active site pocket (H100, E147, E149) were overpro-
duced in E. coli as stable proteins of the predicted size (Figure 3D).
Two of these were localised to the outer membrane (E147 and
E149, Figure 2). All the mutant proteins, except G89A (the only
residue not predicted to be in the active site) exhibited a reduced
ability to degrade arginine-p-nitroanilide (Figure 3D) confirming
that catalysis occurred in the predicted active site pocket.
The DaaaA mutant is unable to grow when the sole
source of carbon and nitrogen is provided by peptides
with amino terminal arginine
P. aeruginosa is able to use arginine as the sole source of carbon
and nitrogen. We therefore thought it possible that by releasing
arginine from peptides, AaaA could provide a valuable source of
arginine to be fed into metabolism for growth in specific
environmental conditions. In rich media sources of carbon and
nitrogen are plentiful. It was therefore no surprise that the DaaaA
mutant grew similarly to its parent in rich media (Figure S1B). To
establish whether the DaaaA mutant could import and metabolise
arginine as well as its parent, we compared the growth of both in
minimal medium (MMP) containing arginine as the sole carbon
and nitrogen source [52,53]. As can be seen in Figure 5A, both
PAO1 and PAO1DaaaA grew equally well.
Interestingly, and in support of our hypothesis, when the
peptide Arg-Gly-Asp was included in MMP as the sole source of
carbon and nitrogen, the DaaaA mutant could not grow although
the wild type P. aeruginosa PAO1 grew well (Figure 5B). The
presence of the complementation vector (pME6032::aaaA) restored
the growth of the DaaaA mutant to a level close to wild type
(Figure 5B), indicating that there were no second site mutations
underlying the growth deficiency observed in the DaaaA mutant.
Taking advantage of the growth deficiency exhibited by the
DaaaA mutant, we were able to further define the specificity of the
AaaA peptidase. The Phenotype Microarrays (Biolog Inc) enable
the simultaneous comparison of a range of two thousand
phenotypes including substrate utilisation and various chemical
sensitivities, using cellular respiration as a reporter. We screened
the DaaaA mutant and its parent, PAO1, to compare their ability
to utilise 380 nitrogen sources including 24 arginine-containing
dipeptides. The data is plotted as respiration over time (data not
shown), and the area under these curves (AUC) has been
calculated and normalised by subtraction of respiration in the
absence of a nitrogen source in order to enable determination of
fold induction of respiration in the mutant (Figure 6). Both PAO1
and PAO1DaaaA respired poorly in the absence of a nitrogen
source and mirrored each other on a number of other nitrogen
sources. For example, both PAO1 and PAO1DaaaA respired
similarly if L-arginine was provided, whilst in the presence of lysine
respiration was on a par with the negative control in which no
nitrogen source was provided (Figure 6, data not shown). For all
the non dipeptide nitrogen sources, if respiration levels indicated
utilization (AUC.negative control), PAO1 and PAO1DaaaA
respired equally well (fold induction ,1), or the mutant respired
better (fold induction .1). Notably, the wild type and DaaaA
mutant respired equally well with all the dipeptides where arginine
was placed at the C-terminus (fold induction ,1). In contrast, with
the exception of Arg-Arg and Arg-Lys dipeptides as the source of
nitrogen, all the dipeptides with an amino terminal arginine
supported better respiration of PAO1 than of the DaaaA mutant
(Figure 6). The extent of this phenotypic difference observed
between the wild type and DaaaA mutant varied slightly depending
on the dipeptide. The greatest difference in the respiration of the
DaaaA mutant compared to the WT was exhibited with the
dipeptides containing Arg-Ile and Arg-Val (Figure 6)
The DaaaA mutant is deficient in long term survival in a
mouse chronic wound infection model
Since ATs are notorious for their role in pathogenicity, we set
out to establish whether AaaA contributed to P. aeruginosa virulence
in an animal infection model. Although the wild type and DaaaA
mutant were able to establish an acute infection in a mouse burn
wound model equally well, there was a difference in virulence in a
chronic mouse wound model [54]. As can be seen in Figure 7A,
the DaaaA mutant showed significantly reduced survival in a
mouse wound chronic infection in comparison to wild type both 2
days and 8 days post infection.
To discount the possibility of secondary site mutations
attenuating virulence, aaaA and its adjacent promoter were
The relative activities of each mutant AaaA in the arginine-p-nitroanilide assay determined as described in Figure 4 are listed below their respective
lane on the immunoblot in Panel D. The activity following incubation of cells with the substrate for 6.5 h is shown as this was the point when wild
type AaaA reached maximal absorbance at 405 nm. The absorbance at 405 nm was adjusted to the level of AaaA made in each particular case by
dividing by the amount of AaaA quantified from the immunoblot using densitometry performed with the ImagJ software. The standard error of the
mean (SEM) for each is also shown.
doi:10.1371/journal.ppat.1002854.g003
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Table 1. Bacterial strains and plasmids used in this study.
Strain/plasmid Description Source
E. coli
BL21[DE3] F2 ompT gal dcm lon hsdSB(rB
2 mB
2) e¨(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) Protein
overproduction strain
[118]
DH5a F2 endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG O¨80dlacZA¨M15 A¨(lacZYA-argF)U169,
hsdR17(rK
2 mK
+), e¨–Cloning strain
[119]
S17-1e¨pir recA pro hsdR RP4-2-Tc::Mu-Km::Tn7 tmpR, spcR, strR conjugation strain for suicide vectors [120]
LEMO21 BL21[DE3] with a fine controllable T7 lysozyme for tunable membrane protein overproduction [121]
Pseudomonas aeruginosa
PAO1 Nottingham collection wild type strain [122,123]
PAO1A¨aaaA In frame deletion of aaaA in PAO1 This study
PAJL1 CTX1 inserted into the chromosome of PAO1 This study
PAJL2 CTX1::aaaA inserted into the chromosome of PAO1 This study
Plasmids
pBluescript KS+ Cloning vector, ColE1 replicon, ApR Strategene
pDM4 Suicide vector, sacBR, oriR6K, CmR [111]
pDEST42 Gateway cloning vector, colE1 ori, ApR, T7, LacO Invitrogen
pET21a Overexpression plasmid vector, f1 origin, colE1 origin, T7 Promoter, his-tag, lacI, ApR Novagen
pME6032 pVS1-p15A E. coli-Pseudomonas shuttle vector, lacP-Ptac expression vector, TcR [124]
pminiCTX1 Mini CTX1 vector for construction of chromosomal complementation. TcR [112]
pDEST42::aaaA Produces AaaA with a C-terminal Histidine tag from pDEST42 Elise Termine and
Alain Filloux
pME6032::aaaA Produces AaaA with a C-terminal Histidine tag from pME6032 This study
pBluescript::aaaA aaaA cloned into pBluescript KS+ This study
pBluescript::aaaAupstream 600 bp upstream of aaaA amplified with primers aaaAfa and aaaArb and cloned between the
XhoI and HindIII sites of pBluescript KS+
This study
pBluescript::aaaAdownstream 600 bp downstream of aaaA amplified with primers aaafb and aaaArc and cloned between the
HindIII and SpeI sites of pBluescript KS+
This study
pBluescript::A¨aaaA 600 bp flanking aaaA with in frame deletion marked by a HindIII recognition site, cloned into the
XhoI and SpeI sites of pBluescript KS+
This study
pDM4::A¨aaaA aaaA with in frame deletion cloned into XhoI/SpeI sites of pDM4 from pBluescript::A¨aaaA. This study
pET21a::aaaA aaaA cloned into pET21a This study
pET21a::aaaAG89A pET21a::aaaA with mutation changing G89 to A This study
pET21a::aaaAH100A pET21a::aaaA with mutation changing H100 to A This study
pET21a::aaaAD102A pET21a::aaaA with mutation changing D102 to A This study
pET21a::aaaAE147A pET21a::aaaA with mutation changing E147 to A This study
pET21a::aaaAE149A pET21a::aaaA with mutation changing E149 to A This study
pET21a::aaaAD176A pET21a::aaaA with mutation changing D176 to A This study
pET21a::aaaAD277A pET21a::aaaA with mutation changing D277 to A
pCTX::aaaA pCTX::lux containing aaaA and the upstream promoter region This study
Primers
aaaAstart CTACAGCGACAGCTAATGGTTTGAACACggatcca This study
aaaAstartNdeI tatcatatgTTCAAACCATTAGCTGTCGCTG This study
aaaAstartEcoRI CAGgaattcGTGTTCAAACCATTAG This study
aaaAend gaattcGAACTGCCAGTTCACCCCGAG This study
aaaAend His gctATCGATttaGTGATGGTGATGGTGATgGAACTGCCAGTT For cloning into
pME6032, this study
aaaAfa tatctcgagAGGCCATCGAGTACATCA This study
aaaArb ataaagcttCTGGCAGTTCTGAGCG This study
aaaAfb tataagcttAATGGTTTGAACACGGCAC This study
aaaArc tatactagtATCTGAAGAAAGCGAAAGAC This study
aaaAminictxFor GCGGCCGCCGGTGCGCAAGAACTCCCAGC This study
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introduced onto the chromosome of P. aeruginosa DaaaA using
miniCTX1 to create a stable chromosomal complementation for
the 8 day animal infection model (P. aeruginosa PAJL2). In vitro,
PAJL2 grew similarly to PAO1 and the DaaaA mutant in LB
(Figure S2), and degraded comparable levels of arginine-p-
nitroanilide. Although behaving like the DaaaA mutant initially
in the chronic mouse wound infection model, and exhibiting lower
viable cell numbers (colony forming units, cfus) than the WT at 2
days post infection, by 8 days post infection the number of viable
bacteria isolated from the wound site for PAJL2 more closely
resembled the WT than the DaaaA mutant.
In addition to an alteration of bacterial load within a mouse
wound chronic infection, there were also changes in immune
response dependent on the presence of AaaA. Initial analysis
revealed that lower levels of expression of the pro-inflammatory
cytokines TNFa and IL-1a were found in mice colonised with the
DaaaA mutant in comparison to the wild type by RT-PCR (data
not shown). More sensitive qRT-PCR confirmed this, and in
Table 1. Cont.
Strain/plasmid Description Source
aaaAminictxRev GATATCCGCTCAGAACTGCCAGTTCAC This study
GAPDHfor AAGGTCGGAGTCAACGGATT This study
GAPDHrev TTGATGACAAGCTTCCCGTT This study
COX-2for CAGCCAGGCAGCAAATCCT This study
COX-2rev ACATTCCCCACGGTTTTGAC This study
KCfor ATGGCTGGGATTCACCTCAAG This study
KCrev TGAGGGCAACACCTTCAAGG This study
TNFafor ACGGCATGGATCTCAAAGAC This study
TNFarev CGGACTCCGCAAAGTCTAAG This study
IL-1afor CGTCAGGCAGAAGTTTGTCA This study
IL-1arev GTGCACCCGACTTTGTTCTT This study
AttB1-HIP ggggacaagtttgtacaaaaaagcaggctccaccgcaggctccaccat Filloux lab/Invitrogen
AttB2-HIP GGGGACCACTTTTGTACAAGAAAGCTGGGTAGAAAGCTGGGT Filloux lab/Invitrogen
aaaA::G89Af CGCCCGCCAGCAGCG Bases altered to
introduce mutation
underlined, this study
aaaA::G89Ar CCGAGGCGATGACGTTCTGC
aaaA::H100Af CTGGTACTCGGCGCGGCCTACGACACCTACTA Bases altered to
introduce mutation
underlined, this study
aaaA::H100Ar GAACTTCCCGCTGCTGCCG
aaaA::D102Af GCGCGCACTACGCCACCTACTACGGTCGC Bases altered to
introduce mutation
underlined, this study
aaaA::D102Ar CGAGTACCAGGAACTTCCCGCTGCTGCCG
aaaA::E147Af GGCGCCGCCGAGGAAGG Bases altered to
introduce mutation
underlined, this study
aaaA::E147Ar GAAACCGACCACCTCGAGGCCGTT
aaaA::E149Af CGAGGAGGCCGGCCTGCG Bases altered to
introduce mutation
underlined, this study
aaaA::E149Ar GCGCCGAAACCGACCACCTCG
aaaA::D176Af ATGATCAACCTCGCCAGCCTGGTCACC Bases altered to
introduce mutation
underlined, this study
aaaA::D176Ar TCCCAGCAGGTTGGCGCGCT
aaaA::H277AfB TCAACCTGGGCCGACC Bases altered to
introduce mutation
underlined, this study
aaaA::H277ArB GCCGCCGGGAATC
Primers are shown with the 59 terminus on the left.
doi:10.1371/journal.ppat.1002854.t001
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addition showed that the expression of KC and COX-2 were also
lower in mice colonised with the DaaaA mutant in comparison to
the wild type 2 days post infection (Figure 7B).
To investigate the expression of more host factors including
components of the innate immune system linked to arginine
availability in the tissue, the expression of iNOS, Arg1 and Arg2
was quantified and also found to be lower within the mouse wound
infected by the DaaaA mutant in comparison to the wild type 2
days post infection (Figure 7B). In each case host factor expression
in skin infected by the complemented DaaaA mutant matched that
infected by the DaaaA mutant rather than the WT which is in line
with the cfus with the exception of Arg1, which exhibited elevated
expression in the complemented DaaaA mutant 2 days post
infection.
Levels for the cytokine expression at day 8 of the infection are
not shown as levels are low at this point in the infection (data not
shown). As a first step to understanding the potential mechanism
underlying AaaA function in the context of chronic skin infections,
the expression levels of iNOS and Arginase are shown. During
trauma, such as in a skin wound, mammalian arginine require-
ments exceed production [55]. Thus, with limited arginine
available, release of arginine from peptides by AaaA may disrupt
a delicate balance of arginine utilization in host cells. Arginase and
iNOS use arginine as a common substrate, and compete with each
other for this substrate [56]. Although a much more extensive
investigation is required to obtain statistically significant data of
expression collected in parallel to protein levels and activity, there
was an interesting trend. After 8 days of infection, the levels of
iNOS expression rose in mouse skin infected by the DaaaA mutant
compared to the WT and complemented mutant whilst expression
of Arg1 tended towards a fall in the DaaaA mutant. The error in
the measurement of Arg1 at 8 days post infection is higher than for
the other genes analysed, thus data must be viewed with caution
although loose trends can be identified to inform further studies
and maximise the benefit of using an animal model. Whilst iNOS
expression in the skin infected by the complemented DaaaA mutant
mirrored that in PAO1 8 days post infection, Arg1 expression did
not. However, interestingly, the Arg1 induction evident 2 days
post infection had resided by 8 days. Arg2 expression does not
appear strongly influenced by the course of infection, perhaps due
to its different tissue distribution or cellular localisation [56].
Sectioning the colonised skin and staining with hematoxylin and
eosin (H & E) indicated that neutrophils infiltrated all the infected
skin wounds (Figure 7, Panels D–L). Consistent with the lower
Figure 4. AaaA can remove arginine from p-nitroanilide. Panel A. The P. aeruginosa DaaaA mutant alone (open triangles) or bearing either
the empty plasmid pME6032 (open circles) or its derivative carrying aaaA (pME6032::aaaA: closed circles) were treated as described in Figure S2B
except arginine-p-nitroanilide was used as a substrate. WT PAO1 cells were treated similarly (closed triangles), and activities (measured as changes in
A405 nm) are compared against a growth media blank (crosses). Panel B. E. coli DH5a bearing either the empty plasmid pME6032 (open circles) or its
derivative carrying aaaA (pME6032::aaaA: closed circles) were grown in LB until exponential phase, induced with 1 mM IPTG, and then incubated
with arginine-p-nitroanilide as described in Figure S2B. Activities are compared against a growth media blank (crosses). Error bars are+/21 S.D.
(n = 15). All measurements have been corrected for differential growth of bacteria by normalising to an initial OD600 nm of 0.1.
doi:10.1371/journal.ppat.1002854.g004
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cfus, it was difficult to visualise the bacteria in the DaaaA mutant
infected skin (Panels J–L), and they could not be located in the skin
8 day post infection. Interestingly, clumps of bacteria could be
found within the mouse skin sections for PAO1 and the
complemented DaaaA mutant after 2 or 8 days (see asterisk in
Panels D–I). In contrast, bacteria observed for the DaaaA mutant
infection after 2 days, were not located within dense clumps.
Moreover, there was evidence of wound repair for the skin
infected by the DaaaA mutant after 8 days as infiltration by
fibroblasts was observed (Panel K).
Discussion
Here, we show that P. aeruginosa possesses an aminopeptidase,
AaaA. AaaA is an AT that is tethered to the surface of P. aeruginosa
and specifically removes amino terminal arginine from peptides.
Site directed mutagenesis revealed that AaaA aminopeptidase
function relies on key amino acids that are conserved within the
M28.005 aminopeptidase family and are located within the active
site pocket of SGAP [40,43]. Although no specific target peptides
or proteins could be identified, we showed that AaaA released
Figure 5. The activity of AaaA enables P. aeruginosa to grow using the tripeptide arg-gly-asp as the sole source of carbon and
nitrogen. P. aeruginosa PAO1 (closed circles) and its derived aaaA deficient mutant (DaaaA, open circles) alone or bearing pME6032 (vector, open
triangles) or pME6032::aaaA (complemented, closed triangles) were grown to mid-exponential phase before the induction of AaaA production by
1 mM IPTG. Cells were resuspended in MMP to OD600 of 1, and subsequently 20 ml of this solution diluted into 200 ml of MMP containing arginine at
10 mM (Panel A), or 10 mM of the tripeptide arg-gly-asp (Panel B). The graph shows the subsequent growth in the Tecan monitored by observing
the increase in OD492 over time. The data is representative of 3 independent repetitions of this experiment.
doi:10.1371/journal.ppat.1002854.g005
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arginine from the aminoterminus of di and tripeptides. P. aeruginosa
was able to use the liberated arginine as a nutrient for growth,
providing a fitness advantage when arginine-containing peptides
were the sole source of nitrogen in the environment. Colonisation
experiments in mice revealed that whilst AaaA did not confer a
virulence advantage in an acute burn wound infection, it did in a
chronic wound infection. The observed attenuation of the DaaaA
mutant was associated with reduced levels of the cytokine
expression.
The M28 family includes amino and carboxy-specific peptidases
with a range of different specificities that are produced by a diverse
array of organisms (http://merops.sanger.ac.uk). These include
eukaryotes (e.g. humans, mice, plants and nematodes), as well as
bacterial species, including but not limited to Streptomyces,
Escherichia, Vibrio, and Pseudomonas. Despite this diversity of hosts,
the residues of the active sites are conserved [39,49,57,58],
suggesting a common reaction mechanism. The crystal structure
and catalytic mechanism of one of the M28 aminopeptidases,
SGAP, has been elucidated [43]. The residues that maintain the
correct active site conformation were identified, and it was
proposed that a glutamic acid residue plus either a tyrosine or
histidine brought about the formation of the catalytic complex via
interaction with two zinc ligands [40,59]. Our data suggests that
the active site of AaaA incorporates the conserved active site
residues of the M28 family. Moreover, two of them (E147 and
E149) appear to have roles in catalysis or stabilization of the active
site pocket since mutation of them to alanine rendered AaaA
stable, OM localised, but non-functional. Presumably the mutant
proteins are unable to form the enzyme-substrate intermediary
complex. We cannot currently conclude whether AaaA utilizes a
similar or distinct catalytic mechanism to SGAP since the
predicted equivalent of one of the two SGAP catalytically
important active-site residues (Y246) has yet to be mutated in
AaaA. Moreover, the equivalent of the other SGAP active site
residue (E131) in AaaA (E147) generated a mutant protein that
retained 46% activity when replaced by alanine [40]. From the
alignment in Figure 3A however it can be seen that E147 is
adjacent to two other glutamates, whilst SGAP has a run of only
two. It is possible that one the neighbouring glutamates may be
able to substitute as a general base in AaaA in the E147A mutant.
Since E149A retained only 7% activity, it may plays a dominant
role within the active site. However, it is not yet possible to deduct
whether this is for co-ordination of the zinc ions or in catalysis.
Since the H100A mutant was not localised correctly to the OM, its
loss of activity (down to1.5%) could be attributed to mislocalisation
(Figure 2).
The instability of a subset of the active site mutants cannot
currently be explained. Point mutations in ATs produced by other
bacteria have not led to degraded proteins, so this was unexpected
and interesting. Studies are underway to confirm the localisation
of these degraded mutant proteins and we aim to determine the
nature of the stable products observed. Moreover, we predicted
Figure 6. AaaA promotes the ability of P. aeruginosa to respire dipeptides with N-terminal arginine except when adjacent to
Arginine or Lysine. P. aeruginosa PAO1 and its derived aaaA deficient mutant were inoculated into nitrogen minimal media (NMM) alone or NMM
containing the indicated nitrogen source. Cellular respiration/metabolic activity is reported via reduction of tetrazolium dye and plotted against time.
The area under the curve (AUC) for a selection of nitrogen sources following 24 h incubation in each condition is plotted here. The values have been
normalised by subtraction of the AUC of the control (no nitrogen source added) on the respective Biolog plate. Relative respiration is calculated by
the difference between the normalised AUC of wild type and mutant divided by their sum and multiplied by 100. The fold induction was calculated
by dividing the normalised AUC of the mutant by that of the wild type, so a value of 1.0 is no change. Biolog Phenotype microarray plates PM03B and
PM06-08 were used as indicated, and each condition performed in duplicate (results from one are shown).
doi:10.1371/journal.ppat.1002854.g006
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that the C-terminal autotransporter b-barrel domain of AaaA
would have been protected from digestion from exogenous trypsin
due to membrane embedding, and thus parallel studies will
investigate why attempts to detect it have not yet been successful
and why AaaA migrates at a molecular mass approximately
10 kDa larger than predicted. It is not surprising that the
passenger domain could not be detected after trypsin digestion
in the supernatant as the software PeptideCutter (http://web.
expasy.org/peptide_cutter/) indicated that 27 residues can be
digested by trypsin. These were mapped onto the 3D model of
PA0328 using RasMol software, where it was possible locate 14 of
these 27 residues on the surface, thereby indicating that they are
more accessible to digestion by trypsin (residues: 33, 38, 47, 106,
130, 136, 185, 262, 273, 277, 279, 283, 309 and 329). The biggest
fragments of PA0328 which could be released by such digestion
would have a predicted molecular weight of 8.3, 6.2 and 5.6 kDa,
which are too small to be detected.
The mouse wound infection model has reliably identified
virulence factors by revealing attenuated mutants [54,60–72]. The
altered pathogenicity in the chronic wound model was associated
with lower bacterial loads and levels of the proinflamatory
cytokines IL-1a, KC, TNFa, and COX-2. The reduction of
TNFa with a lower level of colonisation is in line with a previous
report suggesting that TNFa is up-regulated during chronic P.
aeruginosa infection [73]. The importance of IL-1 in the defence
against P. aeruginosa is supported by the reduced survival of IL-1-
deficient mice following colonisation with P. aeruginosa [74],
supporting the hypothesis that the presence of IL-1 and TNFa is
disadvantageous to the survival of P. aeruginosa and thus selection
for the acquisition of secreted proteases that actively degrade these
cytokines [75]. Both KC and COX-2 have also been linked with
the progression of P. aeruginosa infection [76,77], and microbial
load may be influencing the expression of all these cytokines. The
influence of microbial load on cytokine levels is in part indicated
Figure 7. The AaaA deficient mutant is less virulent in the chronic mouse wound model. Either the P. aeruginosa wild type PAO1 (black
bars), the DaaaA mutant (white bars), or the complemented DaaaA mutant PAJL2 (grey bars) was inoculated (104 CFU) into a chronic wound in each
of 9 mice. After 2 (3 mice per group) or 8 (7 mice per group) days, wound tissue was removed and the bacterial load was estimated by calculating the
colony forming units (Panel A). Chronically-wounded mice were euthanized at post infection day 2 (3 mice per group) or day 8 (7 mice per group),
and wound tissue was harvested for qRT-PCR to detect the mRNA of the indicated cytokines and other host enzymes in the infected wound tissue as
described in the materials and methods (Panel B and C). Tissue from the wounds of the 2 day infected mice (Panels D,G,J) or 8 day infected mice
(Panels E,F,H,I,K,L) was stained with H&E and is shown at 1006magnification. Images of the P. aeruginosa wild type PAO1 (Panels D,E,F), DaaaA
mutant (Panels G,H,I), and the complemented DaaaA mutant PAJL2 (Panels J,K,L) are shown with infiltrating neutrophils indicated by white
arrows, elongated fibroblasts with a red arrow, single bacterial cells with white arrow heads and clumps of bacteria with a white asterisk. Panels D–
E,G–H,J–K are representative of the wound site and Panels F,I,L are representative of the site of infection below the wound.
doi:10.1371/journal.ppat.1002854.g007
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by the data obtained from the complemented DaaaA mutant. At
day two post infection, the number of viable cells for the DaaaA
mutant and complemented DaaaA mutant were similar, as were all
the cytokines, however by day 8 post-infection the complemented
DaaaA mutant resembled PAO1 in viable cell numbers, although
cytokine levels were not determined. It is not clear why the
behaviour of the complemented DaaaA mutant did not mirror that
of PAO1 exactly, but it could be due to the ectopic localisation of
aaaA and its promoter since the local chromosomal structure or
features may influence expression of aaaA.
There are a number of potential underlying mechanisms that
could lead to reduced pathogenicity of the DaaaA mutant, and
these are depicted in the cartoons in Figure 8. Firstly, the lack of
AaaA may lead to reduced fitness in vivo. The data presented here
clearly shows that AaaA enables P. aeruginosa to release arginine
from the aminoterminus of peptides and feed this into metabolism
to enable growth in vitro, and could thus provide the strength of
numbers to overcome the host defences.
The fitness advantage extended by liberating arginine could be
of particular relevance in anaerobic conditions since in the absence
of oxygen, nitrate and nitrite, P. aeruginosa is able to catabolize
arginine by substrate level phosphorylation to serve as an energy
source for anaerobic growth [78,79]. The presence of arginine in
the environment triggers the regulator ArgR to respond by
activating a set of genes involved in arginine metabolism or uptake
[80]. ArgR works in concert with the anaerobic regulator (ANR;
[53]), and interestingly has been shown to positively regulate aaaA
3.7 fold [51]. In this way arginine metabolism and growth in
anaerobic environments are linked with each other [81] and
AaaA.
Additional information linking AaaA to anaerobic growth can
be inferred by considering the lifestyles of bacteria which harbour
AaaA homologues. For example the uncharacterised Pectobacterium
carotovorum AT ECA2163 is a member of the M28.005 sub-family
with 64% sequence identity with AaaA. P. carotovorum is well known
for its ability to grow in anaerobic environments [82]. Another
observation that could argue for a link between AaaA and
anaerobic growth is the absence of a homologue of AaaA in the
plant pathogen P. syringae DC3000. This is despite the presence of
9 ATs in P. syringae [83], two of which are homologues of the other
AT proteins in P. aeruginosa. Notably, P. syringae DC3000 is known
for its virulence in aerobic conditions within the apoplast of tomato
(an environment with particularly low levels of arginine). P.
aeruginosa colonises many sites where anaerobic or microaerobic
conditions are encountered, both in the environment e.g. water-
logged soils and sediments and in vivo e.g. wound infections, otitis
media, and pulmonary infections including those seen in CF
patients [62,84–87]. [88].
Although the DaaaA mutant was not attenuated in the acute
mouse burn wound model, there was a significant attenuation in
the chronic wound model. The latter, probably more so than the
burn model [54], relies on the formation of biofilms that enable
persistence and immune cell evasion [89,90]. Indeed, dense
clusters of bacteria which may represent biofilms were observed in
mouse skin infected by the wild type and complemented DaaaA
mutant, but were absent from wounds infected by the DaaaA
mutant. A possible explanation could be that there is a growth
advantage conferred by AaaA under anaerobic stress or within
biofilms which leads to increased resistance to attack by immune
cells. We are currently investigating the biofilm formation of the
DaaaA mutant in vitro and in vivo to determine whether this could be
a factor.
There is already a precedent for a pathogenicity mechanism
involving a fitness advantage provided by a protease generating
arginine in anaerobic conditions: the Gram-negative bacterium
Porphyromonas gingivalis relies on the production of an arginine-
specific gingipain peptidase to survive in the anaerobic pockets
within gums where it causes chronic inflammation and destruction
of the bone in which teeth are embedded. Since Por. gingivalis
cannot utilise sugars, it has an absolute requirement for proteins as
a carbon and nitrogen source. The degradative gingipains, are
thus an absolute requirement for growth on medium containing
proteins such as bovine serum albumin [91]. In addition to
endopeptidase activity, the arginine gingipain has an arginine-
specific aminopeptidase activity akin to that of AaaA [92], and we
have shown that AaaA is required for growth in certain
environments.
Alternatively the loss of AaaA may influence virulence because
one of its functions is to activate a bacterial virulence factor in a
similar way to which the AT NalP activates other ATs in Neisseria
meningitidis [93]. It is also possible that AaaA may utilise its
aminopeptidase activity to inactivate a host protein and thereby
aid pathogenicity of P. aeruginosa. Such a mechanism would be
analogous to the modification of the extracellular matrix by the
AT Hap which aids attachment of Haemophilus influenzae [94].
Another way that AaaA might contribute to virulence of P.
aeruginosa is by inactivating or degrading immune system compo-
nents. This would be akin to one of the roles of the Por. gingivalis
gingipains which are involved in direct degradation of host
immune factors including cytokines, immunoglobulins and com-
plement factors [95–97]. Further study is required to assess
whether the lack of any of these mechanisms underlie the
attenuation of the DaaaA mutant in the chronic mouse model.
Recently, modulation of the arginases as a means to enable
microbial pathogenesis has been put forward [56], and suggests an
additional interesting hypothesis to explain why AaaA plays such a
key role in pathogenicity of P. aeruginosa. The limited arginine
availability within skin wounds [55] creates a delicate balance of
arginine utilization within host cells exploited by a range of
pathogens [56]. Arginine can be used as a substrate by host cell
Arginase I and II enzymes which differ in their tissue distribution
and subcellular localization [56]. Both arginase isoforms release
urea and ornithine for metabolism and this leads to the TH2
alternative activation if it occurs in macrophages. Arginine is also a
substrate for the inducible nitric oxide synthase (iNOS). The iNOS
enzyme combines arginine and oxygen to form nitric oxide which
inhibits bacterial growth forming part of the TH1 classical pathway
of macrophage activation. Elevated levels of arginine stimulate
arginase activity in the host and bacterial cells [98]. This will
favour the breakdown of arginine to urea and ornithine. This will,
in turn, reduce the inducible nitric oxide synthase (iNOS) response
because there will no longer be arginine available to act as a
substrate for iNOS [99]. In addition to lowering the amount of
nitric oxide to fight the pathogen, since nitric oxide aids wound
healing [55], its absence will prevent the host regenerating physical
barriers to hinder bacterial colonisation (Figure 8). Whilst a
rigorous study involving infections of mice mutated in the arginase
pathway and inhibitors of AaaA is required to establish this
potential mechanism, the data presented provides tantalising
preliminary data that supports this model. In Figure 7C Arg1 and
iNOS expression were slightly reduced and increased respectively
in the DaaaA mutant compared to the wild type, and in Figure 7K,
an influx of fibroblasts is observed suggesting that wound healing is
occurring.
In support of AaaA releasing arginine from peptides to tip the
balance of host cells towards degrading it via arginase enzymes
rather than producing NO using iNOS (see [100] for a
comprehensive overview of the regulation of immune responses
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by L-arginine), mice deficient in iNOS and TNFa clear P.
aeruginosa from their lungs less efficiently in a malnourished CF
infection model [101]. Interestingly, another important pathogen
(the stomach dwelling Helicobacter pylori) encodes a constitutive
arginase (RocF) that functions in exactly the manner outlined
above, although the RocF arginase is produced directly by the
bacterium. In contrast, our model suggests that the altered
arginine levels generated by AaaA stimulate expression of the host
arginase. RocF consumes arginine and prevents NO production in
cultured macrophages, which is relevant to pathogenicity because
the rocF mutant is more efficiently killed and eliminated by
activated macrophages [102]. Similarly, removal of arginine from
the oral cavity through introduction of Lactobacillus brevis producing
arginine deiminase led to reduced generation of nitric oxide which
was associated with reduced inflammation and has been proposed
as a novel therapeutic to combat periodontal disease [103]. In
contrast to these examples, we are proposing that rather than
acting as an arginase directly, AaaA is generating arginine that
stimulates the expression of the host arginase (an approach taken
by a range of intracellular pathogens [56]). For this to occur, the
arginine released from peptides by AaaA on the surface of P.
aeruginosa would need to remain extracellular rather than being
directly imported into the bacterial cell and used in metabolism. It
is possible that we observed enhanced bacterial growth/respiration
due to the presence of AaaA in vitro by virtue of the growth
conditions employed, which would be very different in vivo. Further
investigation of this will require technology capable of monitoring
metabolites at a single-cell resolution during an infection in situ.
Linking this to iNOS and arginase expression would be ideal to
provide an explanation for the delay in stimulation of iNOS in the
DaaaA mutant compared to PAO1 since this was seen at 8 days,
but not 2 days post infection in the mouse skin (Figure 7B,C).
Clearly AaaA is located on the surface of P. aeruginosa, probably
by virtue of its AT domain, and has arginine-specific aminopep-
tidase activity that can be used to release arginine to provide a
growth fitness advantage. Whilst we were able to show that loss of
AaaA led to attenuation in a mouse chronic wound infection, there
remains a number of interesting hypotheses that might explain the
underlying mechanisms involved in this role in pathogenicity.
Further understanding of the reaction mechanism is also critical
as aminopeptidases play central roles in several disease states (e.g.
stroke, diabetes, cancer, HIV, neuropsychiatric disorders) and
other bacterial infections. Since several naturally occurring
hydroxyethyl isostere dipeptide metallo-aminopeptidase inhibitors
(e.g. bestatin, leuhistin and actinonin) alleviate disease symptoms,
e.g by inhibiting matrix degradation and invasion of extracellular
matrixes by fibrosarcoma cells or decreasing HIV viral load,
metallopeptidases are ideal targets in the search for novel
therapeutic drugs. Furthermore, these enzymes have important
biotechnological applications in the processing of proteins and can
be exploited as a diagnostic tool [45,46].
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of Texas Tech University Health Sciences Center
(Protocol Number: 07044).
Strains and growth conditions
Bacterial strains (see Table 1) were routinely cultured in Luria
Bertani (LB) Broth [104] at 37uC, shaking. Strains were routinely
maintained on LB agar plates and kept frozen in glycerol (20% v/
v) at 280uC. Growth curves were performed in 100 ml cultures
shaken at 200 RPM in 500 ml conical flasks at 37uC, in microtitre
plates monitored in a Infinite 200 (Tecan using Greiner 96 well flat
black plates) or in Biolog phenoarrays (see below). Minimal
Medium P (MMP) comprised Na2HPO4 1.47 g, KH2PO4
0.648 g, MgSO4 0.2 g, FeSO4 0.001 g per litre [52]. Antibiotics
were used at the following concentrations: Ampicillin (100 mg/ml),
Kanamycin (50 mg/ml), Chloramphenicol (37.5 mg/ml), and
Tetracycline (20 mg/ml) for E. coli and Chloramphenicol
(37.5 mg/ml), and Tetracycline (125 mg/ml) for P. aeruginosa. The
tripeptide Arg-Gly-Asp (Sigma) was dissolved in MMP to a
concentration of 20 mM and dispensed in 200 ml volumes to
individual wells of a clear bottomed sterile 96 well plate (Costar).
Bacteria from an overnight culture were resuspended to 1 OD600
unit and washed three times in MMP before inoculation into the
MMP-tripeptide growth medium to 0.1 OD600. Cell growth was
monitored at 37uC in an automated plate reader (Anthos Lucy 1),
over a 24 h period. Arginine (10 mM) was utilized for growth
using the same protocol described for the tripeptide above.
Generation of AaaA specific antibodies
E. coli BL21[DE3](pET21a::aaaA) was grown to OD 0.5 and
induced with 500 mM IPTG for 3 h. Cells were harvested by
centrifuation at 60006g for 10 min, resuspended in SDS-PAGE
loading buffer (50 mM Tris-Cl pH 6.8, 100 mM DTT, 2% w/v
SDS, 0.1% w/v bromophenol blue, 10% w/w glycerol) and
separated through SDS PAGE, and stained with Coomassie blue
(10% w/v Coomassie blue, 40% v/v methanol). The protein band
of the expected molecular mass was electroeluted from the gel
[105], verified as being AaaA by tryptic mass spectrometry
Figure 8. Cartoon Model illustrating a selection of the potential roles AaaA may have within a chronic wound. In Panel A, the P.
aeruginosa WT scenario is depicted, where AaaA (black dots) is present on the surface of P. aeruginosa cells colonising a host. Panel B shows
infection with an AaaA deficient mutant that only has non-AaaA proteins on its surface (grey dots). It is possible that AaaA may: Panel I degrade a
protein on the surface of P. aeruginosa, causing activation that aids infection (represented by removal of the black outline around the grey dots in
Panel A, but not in Panel B), Panel II degrade a host protein/peptide, that may be a component of the host immune system (Panel III) by removing
an aminoterminal arginine (R in circle). These activities may be sufficient to aid pathogenicity, however they may serve to liberate arginine that can be
catabolised by the bacteria (Panel IV) resulting in growth promotion in Panel A that is not evident in the absence of AaaA (Panel B). This may
provide a fitness advantage to the bacteria that improves virulence. In conditions where oxygen is limited, the arginine may provide a particular
advantage (Panel V), potentially enabling formation of biofilms that could both serve to promote colonisation and provide resistance against the
immune system. If only some of the released arginine is utilized by the bacteria, local arginine levels may rise in the host (Panel VI). This could induce
arginase production in host cells (depicted by dark grey box and solid black arrows in Panel A:VI). The arginase enzymes will degrade the arginine,
reducing its availability as a substrate for iNOS (indicated by pale grey box and dashed grey arrows in Panel A:VI). Consequently, there will be lower
levels of nitric oxide (NO) and P. aeruginosa will be able to successfully establish an infection. Alternatively, in Panel B:VI, AaaA is absent from the
invading P. aeruginosa, so there is no degradation of proteins and peptides. This maintains the limited arginine concentration and avoids induction of
arginase in host cells. Consequently, arginine would be available to serve as a substrate for iNOS, and the nitric oxide generated could disable the
bacterial cells and promote wound healing.
doi:10.1371/journal.ppat.1002854.g008
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(performed by the University of Nottingham Proteomics Service)
and used to raise antisera by Harlan essentially as described
previously [105]. Before using, the antisera was incubated with a
cell lysate prepared from P. aeruginosa DaaaA mutant to absorb non-
specific antibodies as previously described [105].
Analysis of P. aeruginosa exoproduct production
The level of haemolysis induced was assessed by the size of the
zone of clearing around colonies grown on Columbia blood agar
(Oxoid). The level of milk protein proteolysis by LasB, alkaline
protease and protease IV [106] was assessed by the zone of
clearing around colonies grown on LB skimmed milk agar (LB
agar+1% (w/v) skimmed milk). The production of elastase was
monitored using elastin-congo red. This was performed by adding
100 ml of spent culture supernatant harvested from an LB
overnight broth culture to 20–30 mg of elastin congo red (Sigma).
Following addition of 1 ml 100 mM Tris-Cl/1 mM CaCl2
pH 7.5, incubation for 4 h at 37uC shaking, and removal of
particulates by centrifugation at 13,0006g for 1 min, the optical
density at 495 nm was measured.
Nitrogen source utilisation by Phenotype Microarray
Nitrogen utilisation was analysed using the Phenotype Micro-
Array technology (Biolog inc). All fluids, reagents and PM Panels
were supplied by Biolog and used according to the manufacturer’s
instructions. Briefly, bacteria were cultured for 16 h on Luria-
Bertani agar plates at 28uC. Cells were harvested with a sterile
cotton swab and suspended in 10 ml of inoculating fluid (IF-0),
and the cell density was adjusted to 85% transmittance (T) on a
Biolog turbidimeter. The minimal media inoculating fluid (IF-0a)
contained 100 mM NaCl, 30 mM triethanolamine-HCl (pH 7.1),
2.0 mM NaH2PO4, 0.25 mM Na2SO4, 0.05 mM MgCl2, 1.0 mM
KCl, 1.0 mM ferric chloride, and 0.01% tetrazolium violet [107].
Before the addition to PM microtiter plates, bacterial suspensions
were further diluted into 12 ml of IF-0a (per plate) in the relevant
inoculating fluid. The carbon source for PM03B, PM06-08
experiments that measure nitrogen and peptide utilization was
20 mM sodium succinate and 2 mM ferric citrate. Substrate
utilization was measured via the reduction of a tetrazolium dye
forming a purple formazan (supplied by Biolog) and is indicative of
active cellular respiration at 28uC. Formazan formation was
monitored at 15 min intervals for 30 h. Kinetic data were
analyzed with OmniLog-PM software. Each experiment was
performed at least twice per strain.
Molecular manipulations
Small-scale preparation of plasmid DNA was performed with a
plasmid purification kit (Qiagen). Chromosomal DNA was
extracted from P. aeruginosa with Promega wizard genomic DNA
kit according to the manufacturer’s instructions. Restriction
enzyme digestions, ligations (T4 DNA ligase, Promega), and
agarose gel electrophoresis in 16TAE buffer (80 mM Tris-acetate
pH 7.8, 19 mM EDTA) were performed using standard methods
[104]. Restriction fragments were routinely purified from agarose
gels using the qiaquick kit (Qiagen). Transformation of E. coli was
carried out by electroporation [108]. Conjugation into P. aeruginosa
was performed by co-culturing E. coli S17-1lpir donor bacteria
with recipient bacteria on LB agar for 6 h at 37uC [109]. The
oligonucleotide primers used in this study are listed in Table 1, and
reactions were performed using gotaq DNA polymerase (Promega)
with the following conditions unless otherwise stated. PCR cycles
included a denaturation of 5 min at 96uC in initially and thereafter
for 30 s followed by annealing for 30 s at a temperature adjusted
according to the Tm of the primers and extension at the
recommended temperature for the DNA polymerase for 1 min/
1 kb amplicon. 30 cycles of amplification were employed followed
by a 10 min final extension. Cloned PCR products were
sequenced on both strands by Geneservice Limited (UK).
Southern blotting was performed as described in [104] on
genomic DNA digested for 3 h at 37uC. The probe was generated
with the template pBluescriptDaaaA and primers aaaAfa and
aaaArc. RT PCR was performed on RNA extracted from mouse
tissue using Tri-Reagent (MRC, Cincinnati, OH) in accordance
with the manufacturer’s specifications. cDNA was prepared by
combining 2 mg of total RNA, 400 U of SuperScript RT
(Invitrogen, Carlsbad, CA), and 500 ng of oligo(dT)(Promega,
Madison WI) and incubating the mixture at 42uC for 1 h, and
boiling for 5 minutes at 95uC. Specific primer sets for genes
encoding murine glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), cyclooxygenase-2 (COX-2), keratinocyte-derived cyto-
kine (KC; an orthologue of IL-8), IL-1a and TNFa (Table 1) were
used to amplify DNA templates in a TC-3000 thermocycler
(Barloworld Scientific Staffordshire, United Kingdom) with GoTaq
DNA polymerase (Promega, Madison WI). PCR products were
run on 1.5% agarose gels containing 10,000 concentrate Gelstar
(Lonza, Rockhand, ME), and the gels were visualized under UV
light.
For quantitative real time PCR (qRT-PCR), RNA was
extracted from tissues stored in RNALater (Ambion) using RNeasy
Mini Kit (Qiagen) following standard procedures. RNA samples
were treated with Turbo DNaseI (Ambion) and purified using the
standard protocol of the RNeasy Minelute Cleanup Kit (Qiagen).
RNA quality was assessed using the Bioanalyser 2100 (Agilent
Technologies). RNA subsequently underwent cDNA synthesis
using SuperScriptII (Invitrogen) and Random Primers (Invitro-
gen). cDNA was purified with MinElute PCR Purification Kit
(Qiagen) following standard procedures. TaqMan Primer-Probes
were selected from the Gene Expression Assays (Applied
Biosystems) as follows Gapdh (Mm_99999915_g), Tnfa
(Mm_00443258_m1), Il1a (Mm_00439620_m1), Arg2
(Mm_00477592_m1), Arg1 (Mm_00475988_m1), Ptgs2 (COX2)
(Mm_00478372_m1), Clcx2 (KC) (Mm_04207460_m1), NOS2
(iNOS) (Mm_00440485_m1). All probes worked within 0.1 of the
efficiency slope. Duplicate biological samples were used for each
condition. PCRs were performed in triplicate 20 ml reactions using
Gene Expression Master Mix (Applied Biosystems) and 10 ng of
cDNA/well on an AB7500 (Applied Biosystems) all under
standard procedures. PCR efficiencies were verified using standard
curves.
Bioinformatic analysis
Alignment of nucleotide and deduced amino acid sequences was
performed using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). Homologous proteins were identified using BLAST
tools (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and peptidase fam-
ily membership interrogated via the merops database (http://
merops.sanger.ac.uk/). Alignments were submitted to the Swiss
Model server to build 3D structures (http://swissmodel.expasy.
org/SWISS-MODEL.html), or 3D structures were downloaded
directly from the protein database bank (http://www.rcsb.org/
pdb/home/home.do;jsessionid = CA3F7454E9278A0456FCD66
26F5BC692). 3D structures were viewed using RasMol Version
2.7.5.2 (Based on RasMol 2.6 by Roger Sayle Biomolecular
Structures Group, Glaxo Wellcome Research & Development,
Stevenage, Hertfordshire, UK), and using this software residues
of choice were highlighted.
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Construction of plasmids used in this study
pBluescript::aaaA was constructed by PCR amplifying aaaA from
the genome of P. aeruginosa PAO1 with primers aaaAstart and
aaaAend and digesting them with BamHI and EcoRI to insert them
into the same sites in pBluescript KS+. pDEST42::aaaA was created
using the directions provided in the Invitrogen Gateway system.
Essentially, the aaaA open reading frame was transferred from an
Entry vector [110] into pDEST42 using the AttB1 sites. Insertions
were screened by molecular weight following PCR amplification with
AttB1-HIP and AttB2-HIP primers (Table 1), and verified
by sequencing. To create the shuttle expression plasmid,
pME6032::aaaA, primers aaaAstartEcoRI and aaaAendhis were used
to amplify aaaA from pBluescript::aaaA. Following digestion with
EcoRI and ClaI, the amplicon was inserted into similarly digested
pME6032 (N.B one of the ClaI recognition sites of pME6032 was
previously methylated to prevent cleavage). pET21a::aaaA was built
by amplifying the aaaA open reading frame from pBluescript::aaaA
with primers aaaAstartNdeI and aaaAend, digesting the amplicon
and pET21a with NdeI and EcoRI, and ligating these together.
Generation of an in-frame deletion mutant of
aaaA. Regions of DNA (approximately 600 bp long) immedi-
ately upstream and downstream of aaaA were amplified with
primers aaaAfa/aaaArb and aaaAfb/aaaArc respectively. The
amplicons were cloned into pBluescript KS+ using restriction
enzymes XhoI/HindIII and HindIII/SpeI respectively (creating
plasmids pBluescript::aaaAupstream and pBluescript::aaaAdown-
stream respectively). The two DNA fragments were then excised
with the same enzyme combinations, ligated together to generate
an in-frame deletion at the HindIII site, between the XhoI and SpeI
restriction enzyme recognition sites of pBluescript. The resultant
plasmid, pBluescriptDaaaA, encodes only the first 5 and last 3
amino acids of the native AaaA separated by two residues (S and
F), and was digested with XhoI/SpeI to excise the approximately
sized 1.2 kb DNA fragment that was ligated into the suicide vector
pDM4 [111] that had been similarly digested. The resultant
plasmid (pDM4DaaaA) was electroporated into E. coli S17-1lpir
and chloramphenicol resistant colonies selected, which were
conjugated to P. aeruginosa PAO1 (Nottingham). Transconjugant
P. aeruginosa were selected by growth on Pseudomonas isolation agar
(Difco) containing chloramphenicol. To select for the second
crossover event, transconjugants were grown for 24 h at 37uC in
LB broth containing 5% (w/v) sucrose. These cultures were
subsequently streaked onto LB agar containing 5% (w/v) sucrose,
and grown overnight at 37uC. Colonies which were obtained here
were streaked onto LB agar plates containing chloramphenicol to
ensure none retained CmR phenotype. The DaaaA mutant was
confirmed by screening by PCR with primers aaaAfa and aaaArc
which flank the region deleted. The absence of point mutations
was verified by sequencing of this amplicon.
Generation of chromosomal complemented DaaaA
mutant. aaaA and its upstream promoter were amplified using
the primers aaaAminictxFor and aaaAminictxRev (see Table 1),
and inserted into the pminiCTX1 multicloning site [112] following
restriction digestion of the amplicon and vector with enzymes NotI
and EcoRV. The resultant plasmid (pCTX::aaaA) was electropo-
rated into the DaaaA mutant with selection on tetracycline,
creating PAJL1. Flip recombinase-mediated excision of unwanted
plasmid sequences was performed as described previously [112],
creating the complemented DaaaA mutant (DaaaA::CTXaaaA) which
was named PAJL2.
Site directed mutagenesis
Desired site directed mutations were prepared using the Phusion
site directed mutagenesis kit (according to the manufacturer’s
instructions, Finnzyme). The template used was pBluescript::aaaA.
Following PCR with one mutagenic primer and one non-
mutagenic primer (both 59 phophorylated, see Table 1), ligation
reactions with T4 DNA ligase (Promega) were performed for 3 h
at 22uC. Products were electroporated into E. coli DH5a, and
plasmids with the mutation (as determined by DNA sequencing),
were amplified with primers aaaAstartNdeI and aaaAend, digested
with EcoRI/NdeI to excise the mutated version of aaaA which was
inserted into similarly digested pET21a (Novagen). In the case of
the D102A mutation, direct subcloning was performed with
BamHI and EcoRI. For protein overproduction, the pET21a::aaaA
derivatives were electroporated into E. coli BL21[DE3] or
LEMO21, and induced at mid exponential phase with 1 mM
IPTG (Sigma) for 1–3 h at 37uC with 200 RPM shaking.
p-nitroanilide degradation assay
Stock solutions (20 mM) of p-nitroanilide derivatives (Sigma)
were prepared. Arginine-p-nitroanilide hydrochloride was dis-
solved directly in MMP. Methionine-p-nitroanilide initially in
ethanol:PBS (50:50), whilst Leucine-p-nitroanilide and lysine-p-
nitroanilide required initial solubilisation in methanol. All assays
contained a final concentration of 1 mM of a p-nitroanilide
derivative in MMP. Bacteria were resuspended to 1 OD600 unit
and washed three times in MMP using centrifugation at 13,0006g
for 1 minute and subsequent resuspension in a final volume of
1 ml of MMP. This suspension was used to inoculate 200 ml of
MMP containing the p-nitroanilide reaction mixture in individual
wells of sterile clear bottomed 96 well plates (Costar). Cells were
inoculated to 0.1 OD600 and the degradation of p-nitroanilide
monitored by observing OD405 for 24 h at 37uC in an automated
plate reader (Anthos Lucy 1). If cell lysates were used as the source
of enzyme, they were harvested into MMP, sonicated on ice for
10 seconds and the lysate was cleared by centrifugation at
13,0006g for 1 minute, with the resultant supernatant being
added to the substrate and incubated as described above. In
parallel, 0.027 units of active SGAP (Sigma catalogue number
A9934) were incubated with the p-nitroanilides as substrates under
the same reaction conditions.
Trypsin treatment
Whole cells were collected by centrifugation for 5 min at
3,0006g, washed twice and resuspended to 1 OD600 units/ml in
PBS-Hepes (0.1 M NaCl, 0.002 M KCl, 0.01 M Na2HPO4,
0.01 M KH2PO4 and 10 mM Hepes pH7.4) with or without
Trypsin (1 mg/ml Trypsin: Sigma). In parallel control samples,
Trypsin was inhibited with 50 mg/ml trypsin inhibitor (Soyabean;
Gibco Invitrogen). Cells and protease were incubated at 37uC for
1 h with gentle shaking. Whole cells were harvested by centrifu-
gation at 3,0006g for 5 min, and resuspended in SDS-PAGE
loading buffer (400 ml/OD600 unit of bacteria).
Cell fractionation
Induced cultures (500 ml) were washed with PBS three times
and resuspended in 20 ml PBS. The OD600 nm was normalised to
1.0 in PBS. To prepare the whole cell control, 1 ml was
centrifuged at 60006g for 5 min, and resuspended in 200 ml of
SDS PAGE loading buffer [105]. To prepare the periplasmic and
cytoplasmic fractions, 1 ml of the washed cells was centrifuged at
60006g for 2 min at room temperature, and washed with 300 ml
of 25 mM Tris pH 7.4 three times. The pellet was then
resuspended in 50 ml of 25 mM Tris pH 7.4. and 1 ml of 0.1 M
EDTA and 50 ml of 40% w/w sucrose in 25 mM Tris pH 7.4
were added. The sample was mixed gently at room temperature
for 10 min. Subsequently, the sample was centrifuged and the
Arginine-Specific Aminopeptidase Pseudomonas
PLOS Pathogens | www.plospathogens.org 17 August 2012 | Volume 8 | Issue 8 | e1002854
pellet was resuspended in 100 ml of ice cold 0.5 mM Magnesium
Sulphate. The sample was incubated on ice for 10 min, and
centrifuged for 5 min at 13.0006g. The supernatant was taken as
the periplasmic fraction. The pellet was resuspended in 600 ml of
10 mM Tris pH 7.4 plus 20 mg/mL (PMFS). The sample was
frozen and thawed three times on dry ice. Following this, 19.9 ml,
1 M MgCl2 and 1.2 ml 1 mg/ml DNAase I were added. This was
incubated at 37uC for 15 min. Next, the sample was centrifuged
for 15 min at 13.0006g, and the supernatant contained the
cytoplasmic fraction.
The rest of washed cells (18 ml) was centrifuged for 10 min at
13.0006g and resuspended in 3 ml 20 mM Tris pH 7.4 plus 1 mg
DNAase I and 1 mg RNAase. The sample was passed through the
French Press three times at 16000 lb/in, on ice. Next, the sample
was centrifuged at 20006g for 20 min at 4uC. The resultant
supernatant was centrifuged again 270006g for 40 min at 4uC.
The pellet was resuspended in 200 ml 20 mM Tris pH 7.4 plus
0.7% (Sodium Lauryl Sarcosinate (SLS). The sample was
incubated at 4uC for 25 min and centrifuged at 270006g for
40 min at 4uC. Subsequently, the supernatant contained the inner
membrane fraction and the pellet was resuspended in 200 ml
20 mM Tris pH 7.4 containing the outer membrane.
The samples (periplasmic, inner membrane, cytoplasmic and
outer membrane fractions) were subjected to trichloroacetic acid
(TCA) precipitation. The samples were supplemented to give a
final concentration of 10% TCA, incubated on ice for 30 min, and
centrifuged for 15 min at 130006g. The supernatant was removed
and 500 ml of ice cold acetone added. Following centrifuged for
5 min at 130006g, the supernatants were discarded and pellets air
dried for 15 min. Finally, the pellets were resuspended in 20 ml of
50 mM NaOH plus 180 ml SDS PAGE Loading Buffer [105].
SDS PAGE and immunoblotting
Protein samples were prepared in loading buffer and boiled for
5 minutes before being subjected to SDS-PAGE or immunoblot-
ting as previously described [105]. The mouse a-His monoclonal
antibody (Novagen) was used at a concentration of 1:2000, rabbit
a-RpoS [113] was used at a concentration of 1:10,000, rabbit a-
IcsS was used at 1:1,000 (kind gift from Emma Bouveret), rabbit a-
LEP was used at 1:5000 (kind gift from Vassilis Koronakis [114]),
rabbit a-TolC at 1:2000 (kind gift from Vassilis Koronakis [115]),
rabbit a-AaaA was used at a concentration of 1:1000 following
preadsorption with a bacterial lysate. Binding was detected with
secondary antibodies: a -mouse-HRP (Sigma, used at 1:2000) and
a-rabbit-HRP (Sigma, used at 1:2000). Proteins recognized by the
antibodies were revealed using an ECL detection kit (Pierce) and
photographic film (Amersham) according to the manufacturer’s
instructions. Preadsorption of antisera was performed as described
in [116]. Proteins were quantified by densitometry using ImageJ
software (http://rsbweb.nih.gov/ij/). The protein band of interest
on scanned images of SDS PAGE or Immunoblots was selected
and the profile of density obtained. Gating to select the peak of
interest was undertaken and the area underneath used as the
relative density in the provided units. A matched area of
background from the negative control was subtracted from this
value. Where indicated, fold change was calculated by dividing the
density of one protein band with that of the positive control.
Confocal fluorescent microscopy
The instrument used was Zeiss LSM700, and all manipulations
were performed in a humidifying chamber. Cells were fixed by
mixing with an equal volume of 4% paraformaldehyde (4% v/v)
and incubating for at least 60 min. Aliquots of the fixed bacteria
were air dried onto a microscope slide and re-hydrated in two
changes of freshly prepared Phosphate buffered saline (PBS).
Following incubation in PBS containing 5% (w/v) bovine serine
albumin (BSA) for 60 min, the fixed bacteria were incubated for
2 h with a-AaaA (1:200 final concentration pre-absorbed sera in
PBS-5% BSA). Following thrice washing in PBS, the cells were
incubated for 2 h in donkey a-rabbit alexa fluor 680 conjugated
secondary antibody (1:400 in PBS, Invitrogen). Following three
washes in PBS, the cells were incubated for 5 mins in FM1-43
(1:250 in PBS). After mounting cover slips using fluorescent
mountant (Sigma Flouromount f4680), slides were stored in the
dark until imaging was undertaken on a Zeiss LSM 700. For the
FM1-43 label excitation at 510 nm and emission at 626 nm was
used, and for alexa fluor 680: excitation at 488 nm and emission at
702 nm. Zen software enabled images to be merged and viewed in
either 2D or 3D.
Tissue sectioning, staining, and microscopy
Skin infection sites were formalin-fixed and paraffin embedded.
Sections (5 micron) were taken from a representative area and
stained with hematoxylin and eosin [117].
Mouse models
Mice were administered acute burn and chronic wounds as
previously described [54]. Briefly for chronic wounds, mice were
anesthetized, shaved and administered a dorsal, full-thickness,
1.561.5 cm surgical excision wound. The wounds were covered
with a transparent, semipermeable polyurethane dressing (OP-
SITE, Smith & Nephew, Hull, England) which allowed for daily
inspection of the wound, wound size determination, topical
application of bacteria onto the wound, and protection from
other contaminating bacteria. In addition, the OPSITE dressing
acts as a mechanical barrier to wound contraction, physically
holding the wound open and resulting in a slow-healing wound. A
total of 104 CFU PAO1 or the DaaaA mutant were injected under
the dressing, on top of the wound. Mice were euthanized at 8 days
post-infection and tissue from their wounds was harvested,
weighed and homogenized in sterile PBS. Colonies were
enumerated on LB agar to determine the CFU/g tissue.
Supporting Information
Figure S1 An in-frame deletion mutant of aaaA grows
similarly to its parent in rich medium. (Panel A) The
cartoon indicates the strategy used to generate the DaaaA mutant.
Primer positions are indicated as aaaAfa (a), aaaArb (b), aaaAfb (c),
and aaaArc (d). Genomic DNA from the parental PAO1 and
DaaaA mutant was digested with XmnI, and hybridised to a probe
directed against aaaA. The Southern blot shows the expected sizes
of DNA were detected (wt: 4.8 kb; DaaaA: 2.9 kb). Migration of
marker DNA fragments is indicated in kb on the left. (Panel B)
PAO1 and the DaaaA mutant were grown in LB medium and the
absorbance of the culture at 600 nm is shown plotted against time
of growth.
(TIF)
Figure S2 AaaA does not remove methionine or Leucine
from p-nitroanilide. Panel A. SGAP was incubated with
either leucine-p-nitroanilide (solid circle) or arginine-p-nitroanilide
(open circle) and the resultant changes in A405 nm are shown
against time compared with a buffer blank (crosses). Panel B. The
P. aeruginosa DaaaA mutant (open circles) or WT PAO1 cells (closed
circles) were grown in LB broth until OD600 nm of 1.5, and then
incubated with methionine-p-nitroanilide as described in materials
and methods. Activities are compared against a growth media
blank (crosses) Panel C. The P. aeruginosa DaaaA mutant (open
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circles) or WT PAO1 cells (closed circles) were treated as described
in Panel B, except leucine-p-nitroanilide was used as a substrate.
Activities are compared against a growth media blank (crosses).
Error bars are+/21 S.D. (n = 15). All measurements have been
corrected for differential growth of bacteria by normalising to an
OD600 nm of 0.1.
(EPS)
Figure S3 Insertion of MiniCTX does not significantly
alter the growth profile of P. aeruginosa in LB. Wild type
P. aeruginosa PAO1 (closed triangles), the DaaaA mutant (open
circles) and the DaaaA mutant with insertion of ctx::aaaA PAJL
(closed circles) were inoculated at an OD of 0.06 in LB, and the
growth over 18 h as monitored in the automated plate reader
tecan at 612 nm is shown.
(EPS)
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